RSS

pathogens

Polyphor — a clinical stage Swiss biopharmaceutical company — has raised CHF 6.8 million from the Novo REPAIR Impact Fund to accelerate the development of novel antibiotics against multi-drug resistant Gram-negative pathogens. more

News

Through identifying the way skin reacts to pathogens in older patients, a team of researchers from University College London (UCL) have found that blocking inflammation may help improve vaccine efficacy. more

News